Home > Cardiology > Prasugrel better than ticagrelor in ACS patients undergoing PCI

Prasugrel better than ticagrelor in ACS patients undergoing PCI


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Cardiology
Reuters Health - 09/07/2021  - For patients presenting with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI), a prasugrel-based treatment strategy is superior to using ticagrelor, according to a prespecified subgroup analysis of a randomized clinical trial. "The ISAR-REACT 5 trial (https://bit.ly/2UDEN4N) has demonstrated the superiority of prasugrel to ticagrelor for patients presenting with ACS," said Dr. J. J. Coughlan of the Technical University of Munich, in Germany. "This current study, analyzing outcomes in patients treated with PCI is important for two main reasons," he told Reuters Health by email. "Firstly, PCI is the most frequent treatment strategy for patients with ACS. Secondly, in ACS patients treated with PCI, it has been assumed that pre-treatment with a P2Y12 inhibitor may play an important role. The initial ISAR-REACT 5 study hypothesis, which assumed the superiority of ticagrelor to prasugrel, was based on this p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on